NCT01763333View on ClinicalTrials.gov

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 8, 2013

Primary Completion Date

September 4, 2013

Study Completion Date

September 4, 2013

Conditions
Healthy
Interventions
DRUG

BI 1026706 Placebo

Placebo to BI 1026706

DRUG

BI 1026706

different dose formulations

Trial Locations (1)

Unknown

1320.1.1 Boehringer Ingelheim Investigational Site, Ingelheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY